Packer, M. Butler, J. Filippatos, G.S. Jamal, W. Salsali, A. Schnee, J. Kimura, K. Zeller, C. George, J. Brueckmann, M. Anker, S.D. Zannad, F. Butler, J. Zannad, F. George, J. Brueckmann, M. Perrone, S. Nicholls, S. Janssens, S. Bocchi, E. Giannetti, N. Verma, S. Jian, Z. Spinar, J. Seronde, M.-F. Böhm, M. Merkely, B. Chopra, V. Senni, M. Taddei, S. Tsutsui, H. Choi, D.-J. Chuquiure, E. La Rocca, H.P.B. Ponikowski, P. Juanatey, J.R.G. Squire, I. Butler, J. Januzzi, J. Pina, I. Pocock, S.J. Carson, P. Doehner, W. Miller, A. Haas, M. Pehrson, S. Komajda, M. Anand, I. Teerlink, J. Rabinstein, A. Steiner, T. Kamel, H. Tsivgoulis, G. Lewis, J. Freston, J. Kaplowitz, N. Mann, J. Petrie, M. Bernstein, R. Cheung, A. Green, J. Januzzi, J. Kaul, S. Ping, C.L.S. Lip, G. Marx, N. McCullough, P. Mehta, C. Rosenstock, J. Sattar, N. Scirica, B. Tsutsui, H. Wanner, C. Welty, F.K. Parhofer, K.G. Clayton, T. Pedersen, T.R. Lees, K.R. Konstam, M.A. Greenberg, B. Palmer, M. the EMPEROR-Reduced Trial Committees Investigators Executive Committee National Coordinators Consulting Statistician Clinical Events Committee Scientific Excellence Committee Data Monitoring Committee, Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial, European Journal of Heart Failure, (21), 1270-1278, 2019, John Wiley and Sons Ltd,